How did a pharmaceutical laboratory attached to a small-town pharmacy in the French countryside turn into the eighth largest animal health company in the world while remaining independent?
Beyond the extraordinary family saga Vetoquinol’s success can be measured in milestones. In figures and dates.
In 1933 Joseph Frechin, a pharmacist in Lure (France) launches the “Vetoquinol” an innovative antiseptic. From then on, this is the name under which the family business will be known.
From company creation to acquisition, Vetoquinol wove a web of subsidiaries and distributors.
In 1977, the company set up its first subsidiary abroad, in the Netherlands. Between 1990 and the year 2000, Vetoquinol acquired several companies, namely in Canada and the United States. These purchases marked the beginning of an acquisition policy that continues to this day.
In 2004, the company expanded into China.
With its listing on the stock exchange in 2006, the company acquired new financial resources to establish itself in new markets and continue its expansion. In 2011, Vetoquinol set up operations in Brazil and three years later in Australia. Vetoquinol is now present on all five continents and continues to innovate, produce and market medicines and non-medicinal products.
In 2020, it acquired a range of antiparasitic products for dogs and cats. This combined purchase, the company's largest since its inception, will be followed in 2022 by the launch of another antiparasiticide for cats.
In 90 years, Vetoquinol has become a leading international player in animal health while remaining family owned. Today, the company has more than 2,500 employees in 24 countries.
With a turnover of €540 million in 2022, the company continues to move forward thanks to its boldness, its commitment, and its values.
90 years in animal health and a future to build together.